What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call
Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.
How this was made

The 30-second read
Why it matters
Traders can update models around 2026 revenue, adjusted EBITDA, and Q4 MBR, while also reassessing the credibility of the 2027 growth plan given management’s caution that 2027 does not yet reflect initiative benefits.
Market read
Revised 2026 and Q4 guidance plus Stars and utilization-management execution details are likely to drive near-term repricing of earnings power and risk premium.
What to watch
The guidance explicitly excludes benefits from payment-integrity and clinical initiatives, so investors may be underestimating upside if those initiatives translate into lower appeals/disputes and improved MBR.
Background
The piece summarizes Alignment Healthcare’s Q3 earnings call, focusing on revised 2026 guidance, Q4 operating assumptions, 2027 growth expectations, and Stars/utilization-management execution.
Ticker impact
Alignment Healthcare cut its 2026 outlook, guiding revenue to at least $5.25B and Q4 membership to at least 305,000.
Likely downside bias as the market reprices 2026 earnings power and cost pressures, partially offset by the 2027 growth target.
The article provides explicit revised 2026 revenue, adjusted EBITDA, and Q4 MBR guidance, plus management commentary that higher appeals/disputes and catastrophic-case costs persist.
Market effects
Medicare Advantage plan operators may face similar cost-pressure narratives tied to appeals/disputes and utilization management, reinforcing scrutiny of medical cost trend and Stars execution.
California Stars shortfall highlights regional execution risk for MA plans with concentrated CA exposure.
Limited direct global spillover; primarily impacts US managed-care and Medicare Advantage sentiment.
Counterpoint
The 2027 at-least-20% top-line growth target and Stars remediation efforts could prove more credible than the cautious 2026 framing, supporting a rebound in forward estimates.
Key entities
- companyAlignment Healthcare
Technology-enabled Medicare Advantage insurer providing care coordination and clinical services.
- executiveKao
Management speaker discussing 2027 growth expectations, Stars performance, and utilization-management control.
- executiveHead
Management speaker providing revised 2026 and Q4 guidance assumptions and cost-pressure context.



